Aspira Women’s Health (NASDAQ:AWH) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a research note published on Wednesday.

Aspira Women’s Health Trading Down 3.6 %

AWH opened at $1.06 on Wednesday. The stock’s 50 day simple moving average is $1.39 and its 200-day simple moving average is $2.74. Aspira Women’s Health has a 1 year low of $0.86 and a 1 year high of $6.75. The stock has a market cap of $17.02 million, a PE ratio of -0.73 and a beta of 1.54.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same quarter last year, the company earned ($0.28) earnings per share. Equities analysts forecast that Aspira Women’s Health will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 179,371 shares of the company’s stock after acquiring an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 at the end of the most recent quarter. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.